Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U.

Ann Rheum Dis. 2019 Nov;78(11):1576-1582. doi: 10.1136/annrheumdis-2019-215486. Epub 2019 Aug 7.

PMID:
31391176
2.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F; EUSTAR co-workers.

Clin Rheumatol. 2019 May 20. doi: 10.1007/s10067-019-04564-8. [Epub ahead of print]

PMID:
31111363
3.

[Multimodal rheumatologic complex treatment of rheumatoid arthritis-a monocentric retrospective analysis].

Klemm P, Hudowenz O, Asendorf T, Müller-Ladner U, Lange U, Tarner IH.

Z Rheumatol. 2019 Mar;78(2):136-142. doi: 10.1007/s00393-019-0593-z. German.

PMID:
30715601
4.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

5.

[The rich diversity of Whipple's disease].

Sluszniak M, Tarner IH, Thiele A, Schmeiser T.

Z Rheumatol. 2019 Feb;78(1):55-65. doi: 10.1007/s00393-018-0573-8. Review. German.

PMID:
30552512
6.

Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease.

Rieth AJ, Richter MJ, Berkowitsch A, Frerix M, Tarner IH, Mitrovic V, Hamm CW.

PLoS One. 2018 Sep 20;13(9):e0203947. doi: 10.1371/journal.pone.0203947. eCollection 2018.

7.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

8.

Disease-Specific Effects of Matrix and Growth Factors on Adhesion and Migration of Rheumatoid Synovial Fibroblasts.

Lefèvre S, Schwarz M, Meier FMP, Zimmermann-Geller B, Tarner IH, Rickert M, Steinmeyer J, Sauerbier M, Rehart S, Müller-Ladner U, Neumann E.

J Immunol. 2017 Jun 15;198(12):4588-4595. doi: 10.4049/jimmunol.1600989. Epub 2017 May 12.

9.

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.

Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, Matucci-Cerinic M, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Riccieri V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA.

Rheumatology (Oxford). 2018 Mar 1;57(3):441-450. doi: 10.1093/rheumatology/kex182.

PMID:
28499034
10.

Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease.

Zhou B, Liao Y, Guo Y, Tarner IH, Liao C, Chen S, Kermany MH, Tu H, Zhong S, Chen P.

ORL J Otorhinolaryngol Relat Spec. 2017;79(3):166-177. doi: 10.1159/000452767. Epub 2017 May 3.

PMID:
28463837
11.

Is osteonecrosis of the lunate bone an underestimated feature of systemic sclerosis? A case series of nine patients and review of literature.

Frerix M, Kröger K, Szalay G, Müller-Ladner U, Tarner IH.

Semin Arthritis Rheum. 2016 Feb;45(4):446-54. doi: 10.1016/j.semarthrit.2015.07.010. Epub 2015 Aug 4. Review.

PMID:
26493463
12.

[Molecular effects of physical therapy. What's new?].

Lange U, Tarner IH, Dischereit G, Müller-Ladner U.

Z Rheumatol. 2015 Apr;74(3):226-9. doi: 10.1007/s00393-014-1544-3. German.

PMID:
25854157
13.

[Modern disease-modifying antirheumatic drugs].

Müller-Ladner U, Richter K, Tarner IH.

Internist (Berl). 2015 Mar;56(3):307-14. doi: 10.1007/s00108-014-3651-2. German.

PMID:
25700648
14.

[Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Tarner IH, Albrecht K, Fleck M, Gromnica-Ihle E, Keyßer G, Köhler L, Kötter I, Krüger K, Kuipers J, Nüßlein H, Rubbert-Roth A, Wollenhaupt J, Schneider M, Manger B, Müller-Ladner U; internationalen 3e-Initiative.

Z Rheumatol. 2014 May;73(4):363-73. doi: 10.1007/s00393-013-1249-z. German.

PMID:
24590079
15.

Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.

Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sárdy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N; all participating DNSS centers.

Ann Rheum Dis. 2015 Apr;74(4):730-7. doi: 10.1136/annrheumdis-2013-204487. Epub 2014 Jan 3.

16.

[New therapy strategies].

Müller-Ladner U, Tarner IH.

Z Rheumatol. 2013 Nov;72(9):851-2. doi: 10.1007/s00393-013-1138-5. German. No abstract available.

PMID:
24193187
17.

Interferon-α abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis.

Abeler-Dörner L, Rieger CC, Berger B, Weyd H, Gräf D, Pfrang S, Tarner IH, Schwarting A, Lorenz HM, Müller-Ladner U, Krammer PH, Kuhn A.

J Rheumatol. 2013 Oct;40(10):1683-96. doi: 10.3899/jrheum.121299. Epub 2013 Sep 15.

PMID:
24037549
18.
19.

Acute haemodynamic response to carbon dioxide hand immersion in patients with systemic sclerosis evaluated by Doppler ultrasonography.

Müller-Eschner M, Albrecht K, Tarner IH, Müller-Ladner U, Strunk J, Lange U.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):184-5. Epub 2012 Nov 29. No abstract available.

PMID:
23191999
20.

Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Dischereit G, Tarner IH, Müller-Ladner U, Lange U.

Clin Rheumatol. 2013 Mar;32(3):377-81. doi: 10.1007/s10067-012-2128-8. Epub 2012 Nov 24. No abstract available.

PMID:
23179009
21.

Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany.

Tarner IH, Erkal MZ, Obermayer-Pietsch BM, Hofbauer LC, Bergmann S, Goettsch C, Madlener K, Müller-Ladner U, Lange U.

Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):517-23. doi: 10.1055/s-0032-1321808. Epub 2012 Sep 6.

PMID:
22956254
22.

The role of corticosteroids for pain relief in persistent pain of inflammatory arthritis: a systematic literature review.

Tarner IH, Englbrecht M, Schneider M, van der Heijde DM, Müller-Ladner U.

J Rheumatol Suppl. 2012 Sep;90:17-20. doi: 10.3899/jrheum.120337. Review.

PMID:
22942324
23.

Measuring pain and efficacy of pain treatment in inflammatory arthritis: a systematic literature review.

Englbrecht M, Tarner IH, van der Heijde DM, Manger B, Bombardier C, Müller-Ladner U.

J Rheumatol Suppl. 2012 Sep;90:3-10. doi: 10.3899/jrheum.120335. Review.

PMID:
22942322
24.

[In-vitro study on dissection of inflamed synovial tissue by hydro-jet cutting].

Wagner KH, Tarner IH, Lange U.

Z Rheumatol. 2012 Oct;71(8):707-10. doi: 10.1007/s00393-012-1010-z. German.

PMID:
22911435
25.

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.

Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Tarner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JW, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Ostergaard M, Westhovens R, Zochling J, van der Heijde D.

Rheumatology (Oxford). 2012 Aug;51(8):1416-25. doi: 10.1093/rheumatology/kes032. Epub 2012 Mar 24.

26.

Antitumor necrosis factor-α antibody-coupled gold nanorods as nanoprobes for molecular optoacoustic imaging in arthritis.

Fournelle M, Bost W, Tarner IH, Lehmberg T, Weiß E, Lemor R, Dinser R.

Nanomedicine. 2012 Apr;8(3):346-54. doi: 10.1016/j.nano.2011.06.020. Epub 2011 Jul 6.

PMID:
21740888
27.

Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease.

Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP, Tarner IH, Maurer B, Walder M, Michel B, Gay S, Smolen JS, Müller-Ladner U, Schett G, Distler O.

Ann Rheum Dis. 2011 Jul;70(7):1197-202. doi: 10.1136/ard.2010.140657.

28.

EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research.

Beyer C, Distler JH, Allanore Y, Aringer M, Avouac J, Czirják L, Cutolo M, Damjanov N, Del Galdo F, Fligelstone K, Guiducci S, Kowal-Bielecka O, van Laar JM, Martucci-Cerinic M, Müller-Ladner U, Riemekasten G, Tarner IH, Tyndall A, Kennedy AT, Valentini G, Vettori S, Walker UA, Denton C, Distler O; EUSTAR Biobanking Group.

Ann Rheum Dis. 2011 Jul;70(7):1178-82. doi: 10.1136/ard.2010.142489. Epub 2011 Feb 1.

29.

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.

Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M; EUSTAR Group.

Ann Rheum Dis. 2011 Mar;70(3):476-81. doi: 10.1136/ard.2010.136929. Epub 2010 Nov 15.

PMID:
21081523
30.

Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!

Müller-Ladner U, Tarner IH, Hamm C, Lange U.

F1000 Med Rep. 2010 Apr 12;2. pii: 27. doi: 10.3410/M2-27.

31.

[Biologics and cardiovascular risk].

Tarner IH, Müller-Ladner U, Hamm C.

Z Rheumatol. 2010 Oct;69(8):702-6, 708-11. doi: 10.1007/s00393-009-0583-7. German.

PMID:
20862482
32.

Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.

Söderström K, Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13028-33. doi: 10.1073/pnas.1000546107. Epub 2010 Jul 6.

33.

Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts.

Neumann E, Riepl B, Knedla A, Lefèvre S, Tarner IH, Grifka J, Steinmeyer J, Schölmerich J, Gay S, Müller-Ladner U.

Arthritis Res Ther. 2010;12(3):R83. doi: 10.1186/ar3010. Epub 2010 May 12.

34.

[A wolf in sheep's clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease].

Tarner IH, Lange U, Madlener K, Classen K, Kandolf R, Sperzel J, Müller-Ladner U.

Med Klin (Munich). 2010 Apr;105(4):300-4. doi: 10.1007/s00063-010-1048-0. German.

PMID:
20455054
35.

[Interdisciplinary emergencies in rheumatic diseases].

Tarner IH.

Dtsch Med Wochenschr. 2010 Apr;135(14):683-94; quiz 695-8. doi: 10.1055/s-0030-1251920. Epub 2010 Mar 31. German.

PMID:
20358496
36.

Synovial fibroblasts spread rheumatoid arthritis to unaffected joints.

Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnäker EM, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Schölmerich J, Pap T, Müller-Ladner U, Neumann E.

Nat Med. 2009 Dec;15(12):1414-20. doi: 10.1038/nm.2050. Epub 2009 Nov 8.

38.

[Rheumatology 2009].

Tarner IH, Müller-Ladner U.

Dtsch Med Wochenschr. 2009 Jun;134(25-26):1340-2. doi: 10.1055/s-0029-1225287. Epub 2009 Jun 10. German. No abstract available.

PMID:
19517327
39.

[Novel B-cell directed strategies for the treatment of rheumatic diseases].

Tarner IH.

Z Rheumatol. 2009 Jul;68(5):380-9. doi: 10.1007/s00393-009-0438-2. Review. German.

PMID:
19513729
40.

Clinically relevant advances in rheumatoid arthritis therapy.

Müller-Ladner U, Neumann E, Tarner IH.

F1000 Med Rep. 2009 Sep 14;1. pii: 68. doi: 10.3410/M1-68.

41.

The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis.

Tarner IH, Müller-Ladner U, Uhlemann C, Lange U.

Clin Rheumatol. 2009 Apr;28(4):397-402. doi: 10.1007/s10067-008-1059-x. Epub 2008 Dec 17.

PMID:
19089489
42.

Drug delivery systems for the treatment of rheumatoid arthritis.

Tarner IH, Müller-Ladner U.

Expert Opin Drug Deliv. 2008 Sep;5(9):1027-37. doi: 10.1517/17425247.5.9.1027 . Review.

PMID:
18754751
43.

An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells.

Härle P, Pongratz G, Albrecht J, Tarner IH, Straub RH.

Arthritis Rheum. 2008 Aug;58(8):2347-55. doi: 10.1002/art.23628.

44.

Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients.

Manetti M, Neumann E, Milia AF, Tarner IH, Bechi P, Matucci-Cerinic M, Ibba-Manneschi L, Müller-Ladner U.

Arthritis Rheum. 2007 Oct;56(10):3442-7.

45.

[Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

Saar P, Schmeiser T, Tarner IH, Müller-Ladner U.

Hautarzt. 2007 Oct;58(10):844-50. German.

PMID:
17726594
46.

Natural killer cells trigger differentiation of monocytes into dendritic cells.

Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K.

Blood. 2007 Oct 1;110(7):2484-93. Epub 2007 Jul 12.

47.

Laser-mediated microdissection for analysis of gene expression in synovial tissue.

Hashimoto A, Matsui T, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H, Neumann E, Tarner IH, Müller-Ladner U.

Mod Rheumatol. 2007;17(3):185-90. Epub 2007 Jun 20. Review.

PMID:
17564772
48.

Emerging targets of biologic therapies for rheumatoid arthritis.

Tarner IH, Müller-Ladner U, Gay S.

Nat Clin Pract Rheumatol. 2007 Jun;3(6):336-45. Review.

PMID:
17538565
49.

[Pharmacotherapeutic aspects of femoral head necrosis].

Tarner IH, Dinser R, Müller-Ladner U.

Orthopade. 2007 May;36(5):446-50. Review. German.

PMID:
17476478
50.

Analysis of gene expression patterns in systemic sclerosis fibroblasts using RNA arbitrarily primed-polymerase chain reaction for differential display.

Meyringer R, Neumann E, Judex M, Landthaler M, Kullmann F, Scholmerich J, Gay S, Tarner IH, Distler O, Müller-Ladner U.

J Rheumatol. 2007 Apr;34(4):747-53.

PMID:
17407232

Supplemental Content

Loading ...
Support Center